Infectious Disease Control News & Press Release Distribution

Infectious Disease Control

APAC
Global

GSK's Arexvy is a vaccine approved to protect older adults from respiratory syncytial virus (RSV) disease in Malaysia

* Adults aged 60 and over with underlying co-morbidities are at high risk of developing severe infections from RSV * Vaccine showed 82.6% overall vaccine efficacy against RSV-LRTD with 94.6% efficacy observed in adults with co-morbidities vii KUALA LUMPUR, Malaysia, Sept. 25, 2024 /PRNewswire...

2024-09-25 16:45 3635

GSK's Arexvy is a vaccine approved to protect older adults from respiratory syncytial virus (RSV) disease in Malaysia

TVM Capital Healthcare Announces Investment in Human Longevity, Inc. as Part of its Strategy of Supporting Disease Prevention and Healthy Aging

HLI is one of the most established, global longevity science companies and committed to accelerating living to 100+ years of a healthy, active, and mobile life DUBAI, UAE and RIYADH, Saudi Arabia, Sept. 18, 2024 /PRNewswire/ -- TVM Capital Healthcare, an international healthcare expansion and gr...

2024-09-18 16:00 3078

Gates Foundation Report Calls for Targeted Global Health Spending to Save Millions of Children from Malnutrition and Disease

New modeling shows 40 million more children will suffer from hunger's worst effects by 2050 due to climate change, but immediate action could instead boost health, spur economic growth SEATTLE, Sept. 17, 2024 /PRNewswire/ -- In its eighth annual Goalkeepers report released today, the Bill & Meli...

2024-09-17 12:01 3876

GSK shingles vaccine now available in Malaysia

A vaccine for the prevention of shingles in adults aged 50 and over and those aged 18 and over at increased risk KUALA LUMPUR, Malaysia, Sept. 13, 2024 /PRNewswire/ -- GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced the launch of its Herpes Zoster vaccine,Shingrix (MAL24056002ARZ), ...

2024-09-13 15:07 5904

GSK shingles vaccine now available in Malaysia

Sino Innovation Lab Partners with MASSPHOTON to Launch World-Leading Air Sterilizer, Helping to Curb the Spread of Germs

HONG KONG, Sept. 11, 2024 /PRNewswire/ -- The experience of the COVID-19 pandemic has heightened global awareness of air quality and indoor environmental safety like never before. MASSPHOTON and Sino Innovation Lab have joined forces to launch an innovative medical-grade air sterilizer aimed at ...

2024-09-11 16:32 2947

Sino Innovation Lab Partners with MASSPHOTON to Launch World-Leading Air Sterilizer, Helping to Curb the Spread of Germs

Hyundai Bioscience announces XAFTY®, a groundbreaking broad-spectrum antiviral capable of treating COVID-19, mpox, and dengue

* Hyundai Bioscience presents development updates of its broad-spectrum antiviral at the "Disease Prevention and Control Summit 2024" held in Philadelphia, USA. SEOUL, South Korea, Sept. 11, 2024 /PRNewswire/ -- Dr. Heung-Jeong Woo, a vice president of Hyundai Bioscience shared insights on the...

2024-09-11 14:25 4696

Hyundai Bioscience announces XAFTY®, a groundbreaking broad-spectrum antiviral capable of treating COVID-19, mpox, and dengue

Seegene and Springer Nature Launch 'Nature Awards MDx Impact Grants' to Innovate Syndromic PCR Diagnostic Assays

- Nature Awards MDx Impact Grants in partnership with Seegene extends commitment to external innovation. - Global research teams invited to submit proposals to develop new tests for human infectious diseases. Application deadline:December 2, 2024. - Nature Awards to lead the application and eva...

2024-09-02 21:00 4080

Seegene and Springer Nature Launch 'Nature Awards MDx Impact Grants' to Innovate Syndromic PCR Diagnostic Assays

Hyundai Bioscience to conduct phase 3 clinical trial for high-risk group of COVID-19 patients with the goal of emergency use authorization

* "Xafty® can be the only oral COVID-19 treatment that can be prescribed to high-risk group patients who cannot take Paxlovid®" * "While maintaining the current process for emergency use authorization for mild-to-moderate COVID-19 patients, Hyundai Bioscience will expedite Phase 3 clinical tr...

2024-08-28 17:29 2888

Seegene Develops mpox PCR Test Assays following the WHO Global Health Emergency Declaration

- Develops NovaplexTM MPXV/OPXV Assay and NovaplexTM HSV-1&2/VZV/MPXV Assay - Designed to detect four viruses at once using multiplex PCR technology - Utilize dual internal controls to ensure highly reliable test results - Pledges to supply assays meeting the needs of respective countries SE...

2024-08-26 21:00 4400

Seegene Develops mpox PCR Test Assays following the WHO Global Health Emergency Declaration

Antimicrobial Materials Sector Surges Amid Hygiene and Health Revolution

Pandemic-Driven Demand Shifts Focus to Safe, Durable, and Natural Compounds SAN ANTONIO, Aug. 6, 2024 /PRNewswire/ -- The antimicrobial materials industry is experiencing unprecedented growth, fuelled by a heightened focus on hygiene and cleanliness post-pandemic. Customers in the plastics, coati...

2024-08-06 21:00 3152

PHYLEX VACCINE ON TRACK TO COMBAT DEADLY NIPAH VIRUS WITH POSITIVE RESULTS OF IMMUNOGENICITY STUDY

DEL MAR, Calif., Aug. 6, 2024 /PRNewswire/ -- Phylex Biosciences has achieved positive results with its new mRNA nanoparticle vaccine against the Nipah virus in an immunogenicity study conducted in collaboration with scientists of the U.S. Centers for Disease Control and Prevention (CDC) inAtlant...

2024-08-06 20:00 2975

Pfizer's First Dual Indication Vaccine for Respiratory Syncytial Virus (RSV) is Available This Month in Hong Kong

* The first and only bivalent, single-dose vaccine that fights against both RSV A and RSV B has been approved by health authorities inHong Kong and Macau earlier, and is available inHong Kong this month (July 2024) * Helps fight against RSV in older adults aged 60 and above and infants (throu...

2024-07-18 14:41 2757

Research Identifies Blind Spots That Affect Quality of Life Among People with HIV in Singapore

Dedicated mobile app to encourage proactive management of physical health, mental well-being and chronic disease SINGAPORE, July 18, 2024 /PRNewswire/ -- With the advancements in medical sciences, there is now very little difference between the life expectancy of people with HIV (PWH) and the ge...

2024-07-18 13:45 2848

Hyundai Bioscience succeeds in developing 'Multi-treatment for mosquito-borne viral infections' including Dengue Fever

* Developed a 'Niclosamide-based multi-treatment drug' that can simultaneously treat mosquito-borne viral infections such as four serotypes of dengue virus, Zika, Chikungunya, and Yellow Fever. * Accelerating preparations for dengue fever basket clinical trial scheduled to be conducted inBraz...

2024-06-26 09:17 3068

Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress 2024

New translational data demonstrate that BRII-179-induced immune responses are associated with high HBsAg reduction in a subset of participants with chronic HBV infection BRII-179 as add-on therapy induces functional antibody responses and contributes toimproved sustained HBsAg loss in PEG-IFNa-t...

2024-06-07 19:00 4681

HSA approves GSK's Arexvy, the world's first respiratory syncytial virus (RSV) vaccine for older adults [1]

* Arexvy has been approved by the Health Sciences Authority (HSA) of Singapore for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older.[2] * Arexvy is 94.6% efficacious in prevent...

2024-05-16 10:00 3490

HSA approves GSK's Arexvy, the world's first respiratory syncytial virus (RSV) vaccine for older adults [1]

Animal Quarantine Service Uncovers Foreign National Attempting to Bring Livestock Products into Japan Illegally

TOKYO, May 15, 2024 /PRNewswire/ -- Last year, the Animal Quarantine Service (AQS) uncovered a foreign national who illegally brought meat such as sausages containing pork, which are prohibited from being imported toJapan from overseas, intoTokyo International Airport, and recently there was a ca...

2024-05-15 15:00 5183

Everest Medicines Announces Commercial Launch and First Prescription for NEFECON® in Mainland China

SHANGHAI, May 14, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative medicines and vaccines, today announced that NEFECON®, a delayed rel...

2024-05-14 21:41 4162

Pfizer Receives Authorization from Health Authority for the First Dual Indication Vaccine Approved in Hong Kong

A Vaccine to Fight Against Respiratory Syncytial Virus (RSV) in Older Adults Aged 60 and Above and Infants (Through Maternal Immunization) * The first and only bivalent, single-dose vaccine that fights against both RSV A and RSV B disease through two seasons has been approved by Hong Kong Depa...

2024-05-08 16:14 2495

INTREPID Alliance Landscape of Promising Antivirals in Clinical Development Reveals Gaps in Global Defense Against Potential Future Pandemics

Detailed scientific analysis of antiviral pipeline identifies most promising clinical compounds aligned with 100 Days Mission global preparedness recommendations CAMBRIDGE, Mass., April 29, 2024 /PRNewswire/ -- Building on its commitment to identify strengths and gaps in the R&D pipeline for ant...

2024-04-29 12:00 2139

1 2 3 456 7 8 ... 30